Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Investigate the validity of Hemosense System in pediatric patients on anticoagulation therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Blood Coagulation Disorder |
Device: Hemosense (PT/InR point of care device) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements for Pediatric Patients on Anticoagulation Therapy. |
- The compariative accuracy between Point of Care device and standard of care method of determining PT/InR (Laboratory testing using Venous blood Draw)
| Estimated Enrollment: | 200 |
| Study Start Date: | October 2005 |
| Estimated Study Completion Date: | September 2006 |
Over the last few decades there has been an increased use of Warfarin in the pediatric population stemming from the use of mechanical heart valves and palliative surgical procedures requiring anticoagulation therapy. Other patients with enzymatic deficiency within the coagulation cascade may develop thrombosis treated with anticoagulation, i.e. factor V Leiden deficiency. Prevention of poor outcome from thrombosis has required closer monitoring in the pediatric patient. In addition, absorption of Warfarin in the pediatric population is highly variable and depends on the child’s age, weight, diet, and concurrent use of other medications (Desai, 2000). This makes achieving anticoagulation very difficult. “Because of the intrinsic differences in the coagulation systems in children and adults, guidelines for antithrombotic therapy in adults cannot be extrapolated to pediatrics” (Desai, 2000). Therefore, pediatric patients on anticoagulation therapy require frequent lab work to monitor their prothrombin time and international ratios (PT/INR).
There are a number of barriers to care when discussing anticoagulation therapy for pediatric patients. Frequent venous blood draws represent a painful procedure that elicit anxiety and fear which leads to noncompliance. In addition, children are more difficult to obtain blood samples because of smaller vessels, patient movement during procedure, and the volume of blood that is required for the test. Other barriers include the time delay from when the patient has the lab work drawn, to when the result get to the provider for any patient care decisions to be made.
There are a number of Point of Care devices available for near-patient testing of the PT/InR’s that requires only a finger stick. These monitors have been validated against standardized laboratory testing, in order for the monitor to be certified by the FDA. Similar studies to validate finger stick methods in pediatric patients have not been completed. The aim of this project is to validate the accuracy of Hemosense, a point of care device, to venous blood PT/InR level in the pediatric population.
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All pediatric patient requiring Warfarin therapy.
Exclusion Criteria:
- Subjects older then 18 year of age.
- Pregnant subjects.
Contacts and Locations| United States, New York | |
| University of Rochester Strong Medical Center | Recruiting |
| Rochester, New York, United States, 14642 | |
| Contact: Peter H CHANG, D.O. 585-273-5440 psschang@yahoo.com | |
| Principal Investigator: Peter H chang, D.O. | |
| Principal Investigator: | Peter H Chang, D.O. | University of Rochester Strong Memorial Hospital |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00288808 History of Changes |
| Other Study ID Numbers: | 11787 |
| Study First Received: | February 6, 2006 |
| Last Updated: | February 6, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Rochester:
|
Blood Coagulation PT/InR Warfarin Mechanical Valve |
Additional relevant MeSH terms:
|
Blood Coagulation Disorders Hemostatic Disorders Hematologic Diseases |
Vascular Diseases Cardiovascular Diseases Hemorrhagic Disorders |
ClinicalTrials.gov processed this record on May 16, 2013